Abstract
Four different classes of new 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors were synthesized, in order to lower the cytotoxicity exhibited by the lead compound A, via disrupting the linearity and the aromaticity of the biphenyl moiety. Compounds 3, 4, 7a and 8 displayed comparable or better inhibitory activity and selectivity, as well as a lower cytotoxic effect, compared to the reference compound A. The best compound 4 (IC50=160nM, selectivity factor=168, LD50≈25μM) turned out as new lead compound for inhibition of 17β-HSD2.
Keywords:
17β-HSD1; 17β-HSD2; Biphenyl; Cytotoxicity; Osteoporosis.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amides / chemical synthesis
-
Amides / chemistry
-
Amides / pharmacology*
-
Biphenyl Compounds / chemical synthesis
-
Biphenyl Compounds / chemistry
-
Biphenyl Compounds / pharmacology*
-
Cell Survival / drug effects
-
Cytotoxins / chemical synthesis
-
Cytotoxins / chemistry
-
Cytotoxins / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Estradiol Dehydrogenases / antagonists & inhibitors*
-
Estradiol Dehydrogenases / metabolism
-
HEK293 Cells
-
Humans
-
Molecular Structure
-
Structure-Activity Relationship
Substances
-
Amides
-
Biphenyl Compounds
-
Cytotoxins
-
Enzyme Inhibitors
-
Estradiol Dehydrogenases
-
HSD17B2 protein, human